ONEVIEW HEALTHCARE PLC (ONE)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ONE

ONE - ONEVIEW HEALTHCARE PLC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.11
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.24

14 Aug
2025

-0.010

OPEN

$0.24

-4.00%

HIGH

$0.24

732,998

LOW

$0.23

TARGET
$0.34 41.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
ONE: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 2.0 xxx
DPS (cps) N/A xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in EUR.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-2.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx16.2 M
Book Value Per Share xxxxxxxxxxxxxxx2.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-17.2 M
Net Profit Margin xxxxxxxxxxxxxxx-109.52 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-96.17 %
Return on Invested Capital xxxxxxxxxxxxxxx-89.47 %
Return on Assets xxxxxxxxxxxxxxx-45.05 %
Return on Equity xxxxxxxxxxxxxxx-96.17 %
Return on Total Capital xxxxxxxxxxxxxxx-92.23 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-17.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx23 M
Price To Book Value xxxxxxxxxxxxxxx10.09

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.8 M
Capex % of Sales xxxxxxxxxxxxxxx4.65 %
Cost of Goods Sold xxxxxxxxxxxxxxx6 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx29 M
Research & Development xxxxxxxxxxxxxxx17 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

14/08/2025

1

Speculative Buy

$0.34

41.67%

Oneview Healthcare’s half year revenue rose around 36% to EUR6.3m, slightly below Bell Potter’s forecast, with growth driven mainly by non-recurring hardware deployments rather than ongoing fees.

The broker notes recurring revenue up 6.5%, with US hardware deployments generating around 96% higher recurring revenue per endpoint, offsetting the loss of a low-margin Australian customer.

Operating earnings (EBITDA) met expectations due to cost control, highlight the analysts, though gross margins fell to 61% from the larger share of lower-margin hardware sales.

Two contract wins in 1H25 are fewer than the prior period, and while the sales environment remains challenging, pipeline opportunities via channel partner Baxter could support momentum, suggests the broker.

Bell Potter maintains a Speculative Buy rating and a 34c target price.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -2.04 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.19 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

ONE STOCK CHART

FNArena News on ONE

1
FNArena Corporate Results Monitor – 14-08-2025

Aug 14 2025 - Australia
2
FNArena Corporate Results Monitor – 27-02-2025

Feb 27 2025 - Australia
3
Health Is Wealth

Jul 27 2022 - Australia
4
ASX Companies Adopt ESG Global Reporting Tool

Jun 01 2021 - FYI
5
Telehealth: Part Of Healthcare Revolution

May 12 2021 - Australia

Latest Medical Equipment & Devices News

1
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
2
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
3
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
4
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
5
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
6
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
7
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
8
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
9
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
10
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals